Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL	ALK-positive anaplastic large cell lymphoma, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Recruiting	Phase 2	2026-05-20		NCT07013565

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Children's Hospital of Orange County	22
Children's Hospital of Philadelphia	215
Helen DeVos Children's Hospital	5
Medical College of Wisconsin	201
Memorial Sloan Kettering Cancer Center	753
Nationwide Children's Hospital	97
New York Medical College	28
Ohio State University	297
University of Alabama at Birmingham	467
University of North Carolina	30
University of Utah	319

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
New York Medical College	Valhalla	United States	71